Biology of Blood and Marrow Transplantation
Volume 12, Issue 12 , Pages 1343-1349 , December 2006

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation

  • Navin Wadehra

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Sherif Farag

      Affiliations

    • Department of Medicine, Division of Hematology and Oncology, Indiana University, Indianapolis, Indiana
    • Corresponding Author InformationCorrespondence and reprint requests: Sherif Farag, MD, PhD, Department of Medicine, Division of Hematology and Oncology, Indiana University, 635 Barnhill Drive, Indianapolis, IN 46202.
    • ,
  • Brian Bolwell

      Affiliations

    • Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Patrick Elder

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Sam Penza

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Matt Kalaycio

      Affiliations

    • Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Belinda Avalos

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Brad Pohlman

      Affiliations

    • Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Guido Marcucci

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Ronald Sobecks

      Affiliations

    • Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Thomas Lin

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Steven Andrèsen

      Affiliations

    • Hematologic Oncology and Blood Disorders, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Edward Copelan

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio

Received 17 April 2006 ,Accepted 25 August 2006.

  • Image Result

    PFS of all patients (n = 127) with HD who received Bu/Cy/VP16 preparative regimen.

    PFS of all patients (n = 127) with HD who received Bu/Cy/VP16 preparative regimen.

  • Image Result

    OS of all patients (n = 127) with HD who received Bu/Cy/VP16 preparative regimens.

    OS of all patients (n = 127) with HD who received Bu/Cy/VP16 preparative regimens.

  • Image Result

    Cox multivariate regression analyses showing (A) a significant difference in remission status on OS and (B) a statistically significant difference in the presence of bulky disease on OS. CR indicates

    Cox multivariate regression analyses showing (A) a significant difference in remission status on OS and (B) a statistically significant difference in the presence of bulky disease on OS. CR indicates complete remission; PR, partial remission.

  • Image Result
    Overall 8-year actuarial risk for a secondary malignancy was 9%.

    Overall 8-year actuarial risk for a secondary malignancy was 9%.

PII: S1083-8791(06)00601-X

doi: 10.1016/j.bbmt.2006.08.039

Biology of Blood and Marrow Transplantation
Volume 12, Issue 12 , Pages 1343-1349 , December 2006

Article Tools

* Image Usage & Resolution